(NASDAQ: MREO) Mereo Biopharma Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31%.
Mereo Biopharma Group's earnings in 2026 is -$28,099,000.On average, 9 Wall Street analysts forecast MREO's earnings for 2026 to be -$28,504,839, with the lowest MREO earnings forecast at -$31,299,431, and the highest MREO earnings forecast at -$25,151,328. On average, 9 Wall Street analysts forecast MREO's earnings for 2027 to be -$32,576,958, with the lowest MREO earnings forecast at -$39,124,288, and the highest MREO earnings forecast at -$25,151,328.
In 2028, MREO is forecast to generate -$48,865,438 in earnings, with the lowest earnings forecast at -$46,949,146 and the highest earnings forecast at -$50,302,656.